人前列腺生长因子的分离纯化及生物活性鉴定

从人良性增生前列腺组织中经硫酸铵沉淀和肝素－琼脂糖凝胶层析纯化出人前列腺生长因子（ｈＰＧＦ）,纯化倍数约１０００倍,ＳＤＳ－ＰＡＧＥ和等电聚焦电泳示分子量约为１７ｋＤ、等电点同标准ｈＦＧＦ。利用分离培养的人前列腺间质或纤维细胞进行活性鉴定,发现以１．３￣１．７ｍｏｌ／Ｌ ＮａＣｌ洗脱部分为ｈＰＧＦ,活性最高,对间质成纤维细胞有显著刺激增殖作用。     

重组人粒细胞集落刺激因子的纯化

重组人粒细胞集落刺激因子（ｒｈＧ－ＣＳＦ）在工程菌ｐＣＧ－１／ｒｈＧ－ＣＳＦ／ＤＨ５ａ中以无活性的包涵体形式大量表达。经过菌体破碎分离包涵体、包涵体变性复性后,ｒｈＧ－ＣＳＦ的活性得到恢复。用离子交换和疏水层析纯化了ｒｈＧ－ＣＳＦ,比活性达１．５７×１０８ｕ／ｍｇ,纯度大于９８％。     

豆壳过氧化物酶的分离纯化及其性质研究

从豆壳抽提液经硫酸铵分级沉淀,ＤＥＡＥ－ＳｅｐｈａｄｅｘＡ－５０离子交换层析,ＣｏｎＡ－Ｓｅｐｈａｒｏｓｅ４Ｂ亲合层析和Ｂｉｏ－ＧｅｌＰ－６０凝胶过滤,纯化了豆壳过氧化物酶（ｓｏｙｂｅａｎｈｕｌｐｅｒ－ｏｘｉｄａｓｅ,ＳｈＰ）．纯化酶的比活力为７０７７Ｕ／ｍｇ,在ＳＤＳ－ＰＡＧＥ上显示出一条蛋白质带．ＳｈＰ分子量为３８０００,等电点为３．９;ＳｈＰ为一含血红素的糖蛋白,含糖量为１８．７％,光谱学分析揭示,在４０６ｎｍ处有一典型的Ｓｏｒｅｔ带,在５１０ｎｍ和６４０ｎｍ处有特征吸收峰．酶反应的最适ｐＨ在４．０附近,最适温度为４５℃;在ｐＨ２．５～１２．０之间较稳定,７５℃,保温６０ｍｉｎ,酶活力残余６８％,ＳｈＰ是一种良好的耐酸碱、耐热过氧化物酶．动力学分析求得ＳｈＰ的表观Ｋｍ（愈创木酚）为１．６２ｍｍｏｌ／Ｌ,表现Ｋｍ（Ｈ２Ｏ２）为０．３４ｍｍｏｌ／Ｌ．在所测定的化学试剂中,Ｎ－３、ＣＮ－、Ｆｅ３＋、Ｆｅ２＋和Ｓｎ２＋对酶有较强烈的抑制作用,而重金属离子Ａｇ＋、Ｈｇ２＋、Ｐｂ２＋、Ｃｕ２＋、Ｃｒ３＋以及ＳＤＳ和ＥＤＴＡ对酶活力无显著影响     

抗吗啡活性肽的分离纯化及一级结构测定

报道了一种新的具有抗吗啡镇痛活性的肽的分离纯化,并进行部分一级结构测定．狗脑先经醋酸提取,冷冻成干粉,然后上ＳｅｐｈａｄｅｘＧ－５０和Ｓ－ＳｅｐｈａｒｏｓｅＦ．Ｆ柱,最后经ＲＰ－ＨＰＬＣ纯化,鉴定纯度后,测定其抗吗啡镇痛活性,通过ＳＤＳ－ＰＡＧＥ法测得其分子量为８．９ｋＤ．氨基酸序列分析测得该肽的Ｎ端序列为：Ｖ－Ｉ－Ｓ－Ｖ－Ａ－Ｄ－Ｗ－Ｔ－Ｑ－Ｉ－Ｆ－Ｔ－Ｍ－Ｒ－Ｙ－Ｆ－Ｉ－Ｔ－Ｇ－Ｙ－Ｈ－Ｑ－Ｄ－Ｙ－Ｘ－Ｇ－Ｌ－Ｈ－Ｉ－Ｇ．经部分一级结构同源序列检索,未见与此有同源的蛋白质的报道,暂命名该肽为ＣＣ４肽     

人PSP94全长cDNA的获得及PSP94-TNF~Δ融合蛋白的构建

利用ＲＴ－ＰＣＲ从人肥大前列腺组织钓取９４个氨基酸的人前列腺分泌蛋白（ＰＳＰ９４）全长ｃＤＮＡ,序列分析结果与文献报道的完全一致．将ＰＳＰ９４成熟肽与人ＴＮＦα衍生物（ＴＮＦΔ）通过Ｌｉｎｋｅｒ－ＳＡＰＧＴＰ在基因水平上融合成５′ＰＳＰ９４－ＴＮＦΔ,融合基因ＤＮＡ序列分析结果与设计的相符合．５′ＰＳＰ９４－ＴＮＦΔ在大肠杆菌中表达产物分子量约为３１ｋＤ,表达量约占菌体总蛋白量的３５％．以Ｌ９２９细胞和人前列腺癌细胞株ＰＣ－３为靶细胞进行细胞毒分析结果表明,５′ＰＳＰ９４－ＴＮＦΔ融合蛋白既具有ＴＮＦ的细胞毒活性,又具有对前列腺癌细胞ＰＣ－３的杀伤作用     

人主动脉硫酸乙酰肝素蛋白聚糖对培养的人血管壁细胞生长的作用

通过培养的人主动脉平滑肌细胞（ｈＡＳＭＣ）及脐静脉内皮细胞（ｈＵＶＥＣ）,应用３Ｈ－ＴｄＲ参入、Ｎｏｒｔｈｅｒｎｂｌｏｔ分析、逆转录多聚酶链反应（ＲＴ－ＰＣＲ）、放射免疫分析（ＲＩＡ）、和紫外比色法等技术观察了人主动脉中硫酸乙酰肝素蛋白聚糖（ＨＳＰＧ）对ｈＡＳＭＣ和ｈＵＶＥＣＤＮＡ合成的作用及对血小板源生长因子（ＰＤＧＦ）、ＰＤＧＦ受体、转化生长因子β（ＴＧＦ－β）、内皮素－１（ＥＴ－１）或碱性成纤维细胞生长因子（ｂＦＧＦ）基因表达和肾素－血管紧张系统（ＲＡＳ）的影响,结果显示,ＨＳＰＧ明显抑制培养的ｈＡＳＭＣ基础的ＤＮＡ合成（ｃｐｍ值为：１０３８５±３２６３ｖｓ,２５５４１±６４２１,Ｐ＜０．０１）及外源性ＰＤＧＦ诱导的ＤＮＡ合成（ｃｐｍ值为：９８７８±１９４７ｖｓ．１３４８１±４４ｌ０,Ｐ＜０．０５）;抑制ＰＤＧＦＡ链、ＴＧＦ－Ｂｐ和ＥＴ－１ｍＲＮＡ表达,提高ＰＤＧＦａ和β受体ｍＲＮＡ的表达;显著降低ｈＡＳＭＣ培养液中血管紧张素Ⅱ（ＡｎｇⅡ）的浓度和血管紧张素转换酶（ＡＣＥ）的活性,推测ＨＳＰＧ抑制ＰＤＧＦＡ链、ＴＧＦ－β及ＥＴ－１ｍＲＮＡ表达,降低ＡＣＥ活性及ＡｎｇⅡ浓度是其抑制ｈＡＳＭＣ增殖的重要机     

粒细胞集落刺激因子(G-CSF)在大肠杆菌中的高效表达及快速纯化工艺的建立

基因工程重组人粒细胞集落刺激因子（ｒｈＧ－ＣＳＦ）主要用于癌症患者化疗后的粒细胞减少症．在正确克隆人Ｇ－ＣＳＦｃＤＮＡ的基础上,重点对Ｇ－ＣＳＦｃＤＮＡ的５′端进行了较为彻底的修饰,修饰后的基因插入ｐＢＶ２２０载体组建成功ｐＢＶ２２０／Ｇ－ＣＳＦ／２－１７４高效表达载体．表达后ＳＤＳ－ＰＡＧＥ分析其表达最高达５０％以上．根据Ｇ－ＣＳＦ表达形成包涵体这一特性,建立了一条简便、稳定,适用于大规模生产的分离纯化工艺流程．首先分离纯化包涵体,８ｍｏｌ／Ｌ尿素裂解包涵体,稀释复性蛋白,之后一步ＳＰ－ＳｅｐｈａｒｏｓｅＦＦ柱层析至均质．纯化的Ｇ－ＣＳＦ比活性达３．４×１０８Ｕ／ｍｇ蛋白,每升表达菌液回收的Ｇ－ＣＳＦ总活性达１．０６×１０１１Ｕ．纯化产物的Ｎ－端氨基酸序列分析表明,对甲硫氨酸的去除彻底,用于人体时可能具有较小的免疫原性和毒性     

表达新城疫病毒F48E8株融合蛋白基因的重组鸡痘病毒及其免？…

将将城疫病毒（ＮＤＶ）Ｆ４８Ｅ８株融合蛋白基因导入鸡痘病毒（ＦＰＶ）插入载体ｐＥＧＦ１１７５－１的Ｐ７．５启动子下游,得到转移载体ｐＦＧ１１７５－１重组质粒。采用脂质体转染技术,将该质粒转染ＦＰＶ２８２Ｅ株感染的鸡胚成纤维细胞（ＣＥＦ）。,经过多次蓝斑筛选纯化,获稳定的重组病毒ｒＦＰＶ－ＮＤＦ。间接免疫荧光试验表明,ｒＦＰＶ－ＮＤＦ感染的ＣＥＦ中表达了ＮＤＶ的融合蛋白。用ｒＦＰＶ－ＮＤＦ免疫的ＳＦ     

人胚肺成纤维细胞株纤连蛋白结构域N—糖链结构研究

本文应用明胶、肝素亲和层析二步法首先纯化了人胚肺成纤维细胞培养液的纤连蛋白（Ｆｉｂｒｏｎｅｃｔｉｎ,Ｆｎ）,经ＳＤＳ－ＰＡＧＥ鉴定为一条带,然后用胰糜蛋白酶消化纯化的Ｆｎ所获得的酶解液,经分离分别得到明胶结合片段和肝素结合片段,再应用凝集素－ＨＲＰ染色的Ｗｅｓｔｅｒｎ转移电泳法研究糖链结构,结果证实：１．Ｆｎ中明胶结合片段（４４ｋｄ）中含有二天线和多天线复杂型糖链,并接有平分型ＧｌｃＮＡｃ糖基、核     

菠菜铁型超氧化物歧化酶的纯化及性质

用聚丙烯胺梯度凝胶电泳法检测出菠菜ＳＯＤ同工酶谱带中含３条Ｆｅ－ＳＯＤ活性带,菠菜叶Ｆｅ－ＳＯＤ粗提取液经硫酸铵分部沉淀,ＤＥＡＥ－纤维素－Ａ５２和ＳｅｐｈａｄｅｘＧ－１００柱层析,纯化出单一的Ｆｅ－ＳＯＤ活性带,纯化酶的分子量为４２．６ｋＤ,亚基分子量为２１ｋＤ。对金属元素的分析表明,该酶每分子含２．６个Ｆｅ原子,该酶紫外区最大吸收峰为２７８ｎｍ,等电点为４．６,氨基酸组成和其它来源的Ｆｅ－ＳＯ     

Prostatic growth factor: purification and structural relationship to basic fibroblast growth factor

Prostatic growth factor (PrGF) was purified from alkaline homogenates of human benign prostatic hyperplastic tissue by a combination of ammonium sulfate precipitation, heparin affinity chromatography, and cation-exchange chromatography. The 17,600-dalton, basic (pI 10.2) PrGF is related to basic fibroblast growth factor (bFGF) since antisera raised against synthetic peptides with sequence homologies corresponding to an internal peptide and amino- and carboxyl-terminal peptides of bFGF react with the growth factor. The growth factor appears larger than bFGF, suggesting that additional amino-terminal sequences may be present as a result of alkaline extraction in the presence of protease inhibitors.     

The partial purification and characterization of GnRH-like activity from prostatic biopsy specimens and prostatic cancer cell lines

We have investigated the possibility of the secretion of gonadotrophin-releasing-hormone (GnRH)-like peptides by prostatic cancer cells in culture and their presence in cytosolic preparations from human prostatic biopsy specimens. A GnRH-specific radioimmunoassay showed GnRH-like activity in concentrated cytosolic preparations and conditioned media from DU 145, an androgen-insensitive human prostatic cell line and from LNCaP, an androgen-responsive prostatic cancer cell line. GnRH immunoreactivity in culture media correlated directly with cell numbers. HPLC demonstrated that this GnRH-like material co-migrated with synthetic GnRH. This homology between synthetic GnRH and partially purified prostatic GnRH was confirmed following V8 protease and trypsin digestion which resulted in similar alterations in HPLC characteristics. The mean content of GnRH-like activity/g specimen tissue was significantly more in malignant tissue (88.5 ± 80.5 fmol) than in benign (29.6 ± 22 fmol), though more specimens of benign tissue were positive (37/54) than malignant tissue (6/22). This observation, taken with an earlier finding of GnRH-specific receptors in a hormone-sensitive cell line and human cancer specimens provides supportive evidence for the autocrine hypothesis of cell regulation.     

Amino-terminal sequence of a large form of basic fibroblast growth factor isolated from human benign prostatic hyperplastic tissue

Homogenization of human benign prostatic hyperplastic tissue in high ionic strength alkaline buffer containing protease inhibitors resulted in the isolation of a 17,400 molecular weight growth factor. When tissue was homogenized in ammonium sulfate at pH 4.5 without protease inhibitors a smaller, 16,600 dalton, growth factor was isolated. Both growth factors reacted with antisera against synthetic peptides whose sequences corresponded to the amino-terminal (1-12), Internal (33-43) and carboxyl-terminal (135-145) portions of basic fibroblast growth factor (bFGF). This suggested that the smaller growth factor was not a truncated form of (1-146) bFGF and that the larger growth factor may contain additional sequences. Amino-terminal sequencing showed the larger growth factor to have the sequence: Ala-Ala-Gly-Ser-Ile-Thr-Thr-Leu-Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly- Ala-Phe-Pro-. These results show that the larger growth factor is an 8 amino acid extended from of (1-146) bFGF and it is likely that the smaller growth factor is a proteolytic cleavage product of the larger growth factor produced during the extraction procedure.     

Glutathione S-transferases in human prostate

A number of human prostatic tissue biopsies have been analyzed for glutathione S-transferase activity, using 1-chloro-2,4-dinitrobenzene (CDNB) as a substrate. Samples from nine patients (age range 61-90) with benign prostatic hypertrophy who had received no prior chemotherapy had a mean glutathione S-transferase activity of 137 +/- 44 nmol/min per mg with a range of 97-237. A qualitative comparison of the glutathione S-transferase of normal prostate and benign prostatic hypertrophy samples was carried out. Approximately 260-fold purification was achieved using glutathione-Sepharose affinity chromatography, with glutathione S-transferase accounting for approximately 0.19-0.33% of the total protein. Substrate specificity determinations suggested similar, but not identical, glutathione S-transferase subunits in normal prostate and benign prostatic hypertrophy. One- and two-dimensional electrophoresis (isoelectric focusing and 12.5% SDS-polyacrylamide gel electrophoresis) identified at least seven stained polypeptides in the purified glutathione S-transferase preparations. These ranged in Mr from approximately 24,000 to 28,500 and in pI from near neutral to basic. Western blot analysis using polyclonal antibodies raised against rat liver glutathione S-transferase suggested crossreactivity with five of the human isoenzymes in both normal prostate and benign prostatic hypertrophy. One of the glutathione S-transferases, present in both normal prostate and benign prostatic hypertrophy, had an Mr of approx. 24,000 and a near-neutral pI and crossreacted immunologically with a polyclonal antibody raised against human placental glutathione S-transferase (Yf, subunit 7 or pi). These data suggest that four glutathione S-transferases are expressed in human prostate, with subunits from each of the major classes alpha, mu and pi. These are characterized as Ya, Yb, Yb' and Yf (analogous alternative nomenclature subunits 1, 3, 4 and 7).     

A human prostatic growth factor (hPGF): partial purification and characterization

A growth factor capable of stimulating DNA synthesis of BALB/3T3 cells was purified about 1,000-fold from the cytosol of human benign hypertrophic prostates by heparin-Sepharose chromatography; the growth factor bound to the column in the presence of 0.5 M NaCl was eluted with 1.5-1.7 M NaCl. Its molecular weight and isoelectric point were estimated to be 11,000-13,000 and 10.5, respectively. It was sensitive to heat- and acid-treatments but resistant to disulfide-reducing agent. The final preparation was able to stimulate DNA synthesis at 10 ng/ml. The degree of stimulation was dependent on serum concentration in the assay system; the degree of maximum stimulation increased about 5 times as serum concentration increased from 0.2 to 2%.     

Heparin-binding EGF-like growth factor in the human prostate: Synthesis predominantly by interstitial and vascular smooth muscle cells and action as a carcinoma cell mitogen

Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is an activating ligand for the EGF receptor (HER1/ErbB1) and the high-affinity receptor for diphtheria toxin (DT) in its transmembrane form (proHB-EGF). HB-EGF was immunolocalized within human benign and malignant prostatic tissues, using monospecific antibodies directed against the mature protein and against the cytoplasmic domain of proHB-EGF. Prostate carcinoma cells, normal glandular epithelial cells, undifferentiated fibroblasts, and inflammatory cells were not decorated by the anti-HB-EGF antibodies; however, interstitial and vascular smooth muscle cells were highly reactive, indicating that the smooth muscle compartments are the major sites of synthesis and localization of HB-EGF within the prostate. In marked contrast to prostatic epithelium, proHB-EGF was immunolocalized to seminal vesicle epithelium, indicating differential regulation of HB-EGF synthesis within various epithelia of the reproductive tract. HB-EGF was not overexpressed in this series of cancer tissues, in comparison to the benign tissues. In experiments with LNCaP human prostate carcinoma cells, HB-EGF was similar in potency to epidermal growth factor (EGF) in stimulating cell growth. Exogenous HB-EGF and EGF each activated HER1 and HER3 receptor tyrosine kinases and induced tyrosine phosphorylation of cellular proteins to a similar extent. LNCaP cells expressed detectable but low levels of HB-EGF mRNA; however, proHB-EGF was detected at the cell surface indirectly by demonstration of specific sensitivity to DT. HB-EGF is the first HER1 ligand to be identified predominantly as a smooth muscle cell product in the human prostate. Further, the observation that HB-EGF is similar to EGF in mitogenic potency for human prostate carcinoma cells suggests that it may be one of the hypothesized stromal mediators of prostate cancer growth. J. Cell. Biochem. 68:328-338, 1998. © 1998 Wiley-Liss, Inc.     

Immunohistochemistry of acid phosphatase in the human prostate: normal and pathologic. Cytochemistry and biochemistry of acid phosphatases II

Three different antisera against human prostatic acid phosphatase were used for direct and indirect immunohistochemical demonstration of acid phosphatase in paraffin sections of infantile and adult normal, hyperplastic and carcinomatous prostatic tissue. All antisera were prepared in rabbits. Antiserum A was prepared from highly purified acid phosphatase extracted from autopsy specimens. Antiserum B was a concentrate of a commercial antiserum used in radioimmunoassay and was prepared from purified extracts of human seminal fluid. Antiserum C was a peroxidase-conjugated antiserum prepared from purified extracts of human seminal fluid. The specificity of the three antisera was compared using different immunohistochemical methods and tissues. It was comparably high in all three antisera which gave only slightly different staining results in prostatic tissue. The staining results in prostatic carcinoma were only dependent on the titer of the respective antiserum. Carcinomas with a cribriform growth pattern showed variable staining, but always had a positive immunoreactions, provided the titer of the antiserum was sufficiently high. Striking differences were observed in metaplastic, atrophic and hyperplastic prostatic epithelium. The most intense reaction was observed in atrophic glands: it was much less intense in hyperplastic and normal epithelium and negative or slightly positive in metaplastic epithelium.     

Effect of Silodosin,an Alpha1A-Adrenoceptor Antagonist,on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat

Background

A decreased prostatic blood flow could be one of the risk factors for benign prostatic hyperplasia/benign prostatic enlargement. The spontaneously hypertensive rat (SHR) shows a chronic prostatic ischemia and hyperplastic morphological abnormalities in the ventral prostate. The effect of silodosin, a selective alpha_1A-adrenoceptor antagonist, was investigated in the SHR prostate as a prostatic hyperplasia model focusing on prostatic blood flow.

Methods

Twelve-week-old male SHRs were administered perorally with silodosin (100 μg/kg/day) or vehicle once daily for 6 weeks. Wistar Kyoto (WKY) rats were used as normotensive controls and were treated with the vehicle. The effect of silodosin on blood pressure and prostatic blood flow were estimated and then the prostates were removed and weighed. The tissue levels of malondialdehyde (MDA), interleukin-6 (IL-6), chemokine (C-X-C motif) ligand 1/cytokine-induced neutrophil chemoattractant 1 (CXCL1/CINC1), tumor necrosis factor-alpha (TNF-α), transforming growth factor beta 1 (TGF-β1), basic fibroblast growth factor (bFGF) and alpha-smooth muscle actin (α-SMA) were measured. The histological evaluation was also performed by hematoxylin and eosin staining.

Results

There was a significant increase in blood pressure, prostate weight, prostate body weight ratio (PBR), tissue levels of MDA, IL-6, CXCL1/CINC1, TNF-α, TGF-β1, bFGF and α-SMA in the SHR compared to the WKY rat. The ventral prostate in the SHR showed the morphological abnormalities compared to the WKY rat. Prostatic blood flow was decreased in the SHR. However, treatment with silodosin significantly restored the decreased prostatic blood flow in the SHR. Moreover, silodosin normalized tissue levels of MDA, IL-6, CXCL1/CINC1, TNF-α, TGF-β1, bFGF and α-SMA, and it ameliorated ventral prostatic hyperplasia in the SHR excluding blood pressure. Silodosin decreased PBR but not prostate weight in the SHR.

Conclusions

Silodosin can inhibit the progression of prostatic hyperplasia through a recovery of prostatic blood flow.     

Purification and properties of an endothelial cell growth factor from human platelets

An endothelial cell growth factor has been purified about 1,000,000-fold to homogeneity from human platelets by a seven-step procedure. The purified product has an apparent Mr on sodium dodecyl sulfate-polyacrylamide gels of 45,000. The mobility in sodium dodecyl sulfate gel electrophoresis was similar in the presence or absence of reducing agents, indicating that the factor consists of a single polypeptide chain. Maximal stimulation by the purified protein was achieved at a concentration of about 20 ng/ml (440 pM). Heparin did not potentiate the activity, nor did the factor bind to heparin immobilized on Sepharose. The purified factor was heat- and acid-labile; it was active on porcine and human endothelial cells, but not on human foreskin fibroblasts. Chromatofocusing revealed that the pI of the factor was 4.6. The structural and functional characteristics of the platelet-derived endothelial cell growth factor are distinct from previously characterized endothelial cell mitogens with affinities for heparin.